A Predictive Model for Gastric Cancer-Specific Death after Gastrectomy: A Competing-Risk Nomogram
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.This study developed a nomogram to predict gastric cancer mortality after gastrectomy. The tool aids physicians and patients in making informed decisions regarding gastric cancer (GC) treatment outcomes.
Area Of Science
- Oncology
- Epidemiology
- Biostatistics
Background
- Gastric cancer (GC) remains a significant cause of cancer-related mortality worldwide.
- Gastrectomy is a primary treatment modality for gastric cancer, but outcomes vary.
- Assessing cause-specific mortality after gastrectomy is crucial for patient management.
Purpose Of The Study
- To evaluate the likelihood of gastric cancer-specific death versus other causes of death post-gastrectomy.
- To develop and validate a competing-risk nomogram for predicting gastric cancer mortality.
- To aid in patient counseling and clinical decision-making.
Main Methods
- Utilized the Surveillance, Epidemiology, and End Results (SEER) database for patients undergoing gastrectomy (2007-2015).
- Analyzed gastric cancer death and other-cause death as competing risks.
- Calculated cumulative incidence functions (CIF) and developed a competing-risk nomogram.
Main Results
- Analyzed 8,808 patients; 52.90% died from gastric cancer and 14.58% from other causes.
- Five-year cumulative incidence was 50.4% for gastric cancer death and 10.2% for other-cause death.
- Identified key predictors of gastric cancer mortality including age, tumor characteristics, and treatment modalities.
Conclusions
- A validated nomogram accurately predicts gastric cancer-specific mortality post-gastrectomy.
- The nomogram serves as a valuable tool for physicians and patients in clinical decision-making.
- This tool enhances informed discussions about prognosis and treatment strategies.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...